Label: LO SIMPESSE- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit

  • NDC Code(s): 65862-866-94, 65862-866-95
  • Packager: Aurobindo Pharma Limited
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated May 25, 2023

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use LO SIMPESSE safely and effectively. See full prescribing information for LO SIMPESSE. LO SIMPESSETM (levonorgestrel and ethinyl ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)

    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS

    Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including Lo Simpesse, are contraindicated in women who are over 35 years of age and smoke [see Contraindications (4) and Warnings and Precautions (5.1)].

    Close
  • 1 INDICATIONS AND USAGE
    Lo SimpesseTM (Levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy.
  • 2 DOSAGE AND ADMINISTRATION
    2.1 How to Start and Take Lo Simpesse - Begin Lo Simpesse on the first Sunday after the onset of menstruation. If menstruation begins on a Sunday, take the first light pink tablet that day. For ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Lo Simpesse is available in Extended-Cycle Wallets, each containing a 13-week supply of tablets: 84 light pink tablets, each containing 0.1 mg of levonorgestrel and 0.02 mg ethinyl estradiol, and ...
  • 4 CONTRAINDICATIONS
    Lo Simpesse is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include females who are ...
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Thromboembolic Disorders and Other Vascular Conditions - Stop Lo Simpesse if an arterial or deep venous thrombotic/thromboembolic event occurs. Stop Lo Simpesse if there is unexplained loss ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions with the use of COCs are discussed elsewhere in the labeling: Serious cardiovascular events and stroke [see Boxed Warning and Warnings and Precautions ...
  • 7 DRUG INTERACTIONS
    The sections below provide information on substances for which data on drug interactions with COCs are available. There is little information available about the clinical effect of most drug ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - There is no use for contraception in pregnancy; therefore, Lo Simpesse should be discontinued during pregnancy. Epidemiologic studies and meta-analyses have not ...
  • 10 OVERDOSAGE
    There have been no reports of serious ill effects from overdose of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.
  • 11 DESCRIPTION
    Lo Simpesse (levonorgestrel and ethinyl estradiol tablets USP and ethinyl estradiol tablets USP) is an extended-cycle oral contraceptive regimen of 84 light pink tablets each containing 0.1 mg ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - COCs prevent pregnancy primarily by suppressing ovulation. 12.2 Pharmacodynamics - No pharmacodynamic studies were conducted with Lo Simpesse. 12.3 ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - [See Warnings and Precautions (5.2, 5.11)]
  • 14 CLINICAL STUDIES
    In a 12-month multicenter open-label clinical trial, 2,185 women aged 18 to 41 were studied to assess the safety and efficacy of Lo Simpesse, completing the equivalent of 20,937 28-day cycles of ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    How Supplied - Lo Simpesse (Levonorgestrel and Ethinyl Estradiol Tablets USP 0.1 mg/0.02 mg and Ethinyl Estradiol Tablets USP 0.01 mg) are available in an Extended-Cycle Wallets, that contains 84 ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use). Counsel patients about the following information: Cigarette Smoking - Cigarette ...
  • FDA-approved Patient Labeling
    PATIENT INFORMATION - Lo SimpesseTM  (loe sim pe' see) (Levonorgestrel and Ethinyl Estradiol Tablets USP 0.1 mg/0.02 mg and Ethinyl Estradiol Tablets USP 0.01 mg) WARNING TO WOMEN WHO ...
  • INSTRUCTIONS FOR USE
    Lo Simpesse (loe sim pe' see) (Levonorgestrel and Ethinyl Estradiol Tablets USP 0.1 mg/0.02 mg and Ethinyl - Estradiol Tablets USP 0.01 mg) How do I take Lo Simpesse? Take one pill every ...
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 0.1 mg/0.02 mg and 0.01 mg (91 Tablets Pouch)
    NDC 65862-866-94 - Lo SimpesseTM - (Levonorgestrel and Ethinyl Estradiol - Tablets USP 0.1 mg/0.02 mg and - Ethinyl Estradiol Tablets USP 0.01 mg) Rx ...
  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 0.1 mg/0.02 mg and 0.01 mg (91 Tablets Carton)
    NDC 65862-866-95 - Lo SimpesseTM - (Levonorgestrel and Ethinyl Estradiol - Tablets USP 0.1 mg/0.02 mg and - Ethinyl Estradiol Tablets USP 0.01 mg) Rx ...
  • INGREDIENTS AND APPEARANCE
    Product Information